Vertex Pharmaceuticals Incorporated Stock News

Vertex (VRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The healthcare industry tends to do well in all types of economies. Vertex just garnered a new blockbuster approval, and more could be around the corner.

Amazon has multiple business moats and ways to continue growing. MercadoLibre is well positioned to capitalize on the massive opportunities in Latin America.

Healthcare and digital advertising are mammoth industries. Vertex is widening its moat across the rare disease drug market.

Vertex (VRTX) signs a collaboration agreement with TreeFrog to utilize the latter's C-Stem technology in order to optimize the production of its T1D cell therapies.

Vertex has built a billion-dollar business thanks to its expertise in treating cystic fibrosis. The biotech stock is cheaper today than it was earlier this year in relation to expected earnings.

Vertex is a leader in cystic fibrosis treatment but also is showing it can succeed in other disease areas. The company recently won approval for a gene-editing treatment for blood disorders.

One of these magnificent stocks could be a big winner in a new $4 trillion market. Another is a leader in using AI to automate online processes.

Great pharma companies tend to be entrenched in lucrative markets. Vertex Pharmaceuticals is managing to diversify off a strong base.

Eli Lilly has crushed the S&P 500 over the last 12 months and could continue delivering outsized returns. Novo Nordisk's strong fundamentals and solid growth opportunities make it a no-brainer buy.

Biotech stocks offer the possibility of groundbreaking medical advancements alongside the potential for explosive growth. While the sector carries inherent risks, a select group of biotech companies p

Vertex (VRTX) begins rolling NDA submission for its investigational non-opioid candidate, suzetrigine, for acute pain management. The submission is expected to be completed in second-quarter 2024.

Vertex is growing beyond its highly successful cystic fibrosis business and into other areas of healthcare. The added growth opportunities should accelerate its growth rate, which slowed down last yea

Vertex Pharmaceuticals will acquire Alpine Immune Sciences for $4.9 billion. Alpine Immune Sciences' leading candidate looks highly promising.

Vertex Pharmaceuticals (VRTX) closed at $394.17 in the latest trading session, marking a -0.8% move from the prior day.